Tirzepatide, the first approved GLP-1/GIP dual receptor agonist, represents a significant advancement in diabetes and obesity treatment by targeting two incretin hormone pathways simultaneously.
Dual receptor targetingTirzepatide activates both GLP-1 and GIP receptors simultaneously, producing superior blood sugar and weight outcomes compared to single-target drugs
What the researchers found
Tirzepatide is a novel peptide that selectively binds and activates both the GIP and GLP-1 receptors. The review consolidates evidence from multiple clinical trials showing:
- Tirzepatide produces superior blood sugar (HbA1c) reductions compared to GLP-1-only drugs
- It achieves greater weight loss than existing single-target treatments
- The dual GIP/GLP-1 mechanism provides complementary metabolic benefits
- It is already authorized in several countries for type 2 diabetes and obesity
The GIP component adds benefits beyond what GLP-1 activation alone can achieve, including enhanced insulin secretion and potentially different effects on fat metabolism and energy expenditure.
Why it matters
Tirzepatide represents the most significant advance in peptide-based diabetes therapy since the introduction of GLP-1 receptor agonists. By targeting two hormone receptors, it achieves results that single-target drugs cannot match. The fact that it is already approved and prescribed makes this review practically relevant for patients and clinicians. It also sets the stage for even more complex multi-receptor peptide drugs in development.
How the study worked
This is a narrative literature review summarizing the mechanisms of action of GIP/GLP-1 co-agonists and the clinical trial data for tirzepatide. The authors reviewed data from the major clinical development programs including the SURPASS (diabetes) and SURMOUNT (obesity) trial series.
What this study cannot tell us
As a narrative review, this paper synthesizes existing data without presenting new findings. The review was published relatively early in tirzepatide's clinical life, meaning some long-term safety and efficacy data were not yet available. The comparison between GIP/GLP-1 dual agonism and GLP-1 agonism alone is complicated by dose differences and study designs. The relative contribution of GIP versus GLP-1 receptor activation to tirzepatide's clinical effects is still being debated.
How to read the evidence
This is a narrative review drawing on data from multiple large randomized controlled trials (SURPASS and SURMOUNT series). The underlying evidence is high-quality, though the review itself is not a systematic analysis. Tirzepatide's approval by regulatory agencies in multiple countries reflects the strength of its clinical evidence.
When this study was published
Published in 2024, this review reflects the early post-approval period for tirzepatide. Since then, additional clinical data including cardiovascular outcome results have become available, further expanding the evidence base.
The bigger picture
Tirzepatide validates the concept that targeting multiple incretin receptors with a single peptide molecule can produce superior metabolic outcomes. This success has accelerated development of triple agonists (targeting GLP-1, GIP, and glucagon receptors) and other combination peptide approaches. The era of multi-receptor peptide therapeutics — envisioned in earlier research — is now a clinical reality, with tirzepatide as the proof of concept that has reshaped treatment expectations.
Questions still open
- How much of tirzepatide's superior efficacy comes from GIP receptor activation versus optimized GLP-1 receptor engagement?
- Will tirzepatide's cardiovascular outcome data (from the SURPASS-CVOT trial) match or exceed the heart protection seen with GLP-1-only drugs?
- Can triple agonists targeting GLP-1, GIP, and glucagon receptors improve upon tirzepatide's already impressive results?
Common questions
How is tirzepatide different from semaglutide?
Is tirzepatide approved for weight loss?
Read the original research
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes.
Acta diabetologica, 61(8), 941-950
Citation
Ciardullo, Stefano; Morieri, Mario Luca; Daniele, Giuseppe; Fiorentino, Teresa Vanessa; Mezza, Teresa; Tricò, Domenico; Consoli, Agostino; Del Prato, Stefano; Giorgino, Francesco; Piro, Salvatore; Solini, Anna; Avogaro, Angelo. (2024). GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes.. Acta diabetologica, 61(8), 941-950. https://doi.org/10.1007/s00592-024-02300-6